Table 2.
Patient characteristics.
| Parameter |
All patients (N = 93) |
Proven BKPyVAN (n = 40) |
Probable BKPyVAN (n = 7) |
Possible BKPyVAN (n = 23) |
Resolving BKPyVAN (n = 23) |
P* |
|---|---|---|---|---|---|---|
| Demographic characteristics | ||||||
| Age at sample collection (years) | 40.31 ± 10.40 | 40.21 ± 10.44 | 36.23 ± 9.06 | 39.44 ± 10.78 | 42.62 ± 10.44 | 0.503 |
| Sex | 0.406 | |||||
| Male | 54 (58.06) | 20 (50.00) | 5 (71.43) | 16 (69.57) | 13 (56.52) | |
| Female | 39 (41.94) | 20 (50.00) | 2 (28.57) | 7 (30.43) | 10 (43.48) | |
| Height (cm) | 164.01 ± 9.34 | 162.83 ± 10.24 | 167.86 ± 7.31 | 166.78 ± 9.25 | 162.13 ± 7.73 | 0.188 |
| Weight (kg) | 55.22 ± 11.74 | 53.10 ± 11.69 | 59.57 ± 11.43 | 60.28 ± 11.63 | 52.53 ± 10.71 | 0.049 |
| Body mass index (kg/m2) | 20.38 ± 3.21 | 19.93 ± 3.44 | 20.97 ± 2.74 | 21.49 ± 2.88 | 19.87 ± 3.11 | 0.231 |
| Indication for renal transplantation | 0.705 | |||||
| IgA nephropathy | 12 (12.90) | 5 (12.50) | 0 (0.00) | 4 (17.39) | 3 (13.04) | |
| Focal segmental glomerular sclerosis | 2 (2.15) | 1 (2.50) | 0 (0.00) | 0 (0.00) | 1 (4.35) | |
| Nephrotic syndrome | 3 (3.23) | 0 (0.00) | 0 (0.00) | 2 (8.70) | 1 (4.35) | |
| Chronic glomerulonephritis | 22 (23.66) | 9 (22.50) | 2 (28.57) | 6 (26.09) | 5 (21.74) | |
| Lupus nephritis | 3 (3.23) | 1 (2.50) | 0 (0.00) | 0 (0.00) | 2 (8.70) | |
| Diabetic nephropathy | 4 (4.30) | 2 (5.00) | 1 (14.29) | 1 (4.35) | 0 (0.00) | |
| Hypertensive nephropathy | 1 (1.08) | 1 (2.50) | 0 (0.00) | 0 (0.00) | 0 (0.00) | |
| Others/unknown | 46 (49.46) | 21 (52.50) | 4 (57.14) | 10 (43.48) | 11 (47.83) | |
| Transplant characteristics | ||||||
| Donor type | 0.685 | |||||
| Deceased | 82 (88.17) | 37 (92.50) | 6 (85.71) | 20 (86.96) | 19 (82.61) | |
| Living | 11 (11.83) | 3 (7.50) | 1 (14.29) | 3 (13.04) | 4 (17.39) | |
| Induction agent | 0.275 | |||||
| Basiliximab | 23 (24.73) | 9 (22.50) | 1 (14.29) | 4 (17.39) | 9 (39.13) | |
| Thymoglobulin | 68 (73.12) | 30 (75.00) | 5 (71.43) | 19 (82.61) | 14 (60.87) | |
| Basiliximab + thymoglobulin | 2 (2.15) | 1 (2.50) | 1 (14.29) | 0 (0.00) | 0 (0.00) | |
| Delayed graft function | 0.631 | |||||
| No | 84 (90.32) | 36 (90.00) | 7 (100.00) | 20 (86.96) | 21 (91.30) | |
| Yes | 9 (9.68) | 4 (10.00) | 0 (0.00) | 3 (13.04) | 2 (8.70) | |
| Renal replacement therapy: hemodialysis | 0.665 | |||||
| No | 36 (38.71) | 14 (35.00) | 4 (57.14) | 8 (34.78) | 10 (43.48) | |
| Yes | 57 (61.29) | 26 (65.00) | 3 (42.86) | 15 (65.22) | 13 (56.52) | |
| Renal replacement therapy: peritoneal dialysis | 0.669 | |||||
| No | 66 (70.97) | 27 (67.50) | 4 (57.14) | 18 (78.26) | 17 (73.91) | |
| Yes | 27 (29.03) | 13 (32.50) | 3 (42.86) | 5 (21.74) | 6 (26.09) | |
| Length of renal replacement therapy (months) | 20.45 ± 26.60 | 18.04 ± 22.97 | 35 ± 43.87 | 24.62 ± 30.81 | 16.04 ± 20.79 | 0.309 |
| Length of time post-transplant (months) | 21.84 ± 23.05 | 17.43 ± 15.33 | 8.24 ± 9.29 | 7.55 ± 5.08 | 47.94 ± 27.14 | <0.001 |
| Clinical characteristics | ||||||
| Baseline serum creatinine (μmol/L) | 114.76 ± 34.15 | 112.78 ± 37.53 | 111.57 ± 23.06 | 113.48 ± 34.19 | 120.48 ± 31.94 | 0.837 |
| Serum creatinine at sample collection (μmol/L) | 173.61 ± 77.21 | 210.63 ± 89.82 | 153.86 ± 51.67 | 114.57 ± 26.73 | 174.30 ± 54.04 | <0.001 |
| Maintenance immunosuppression | ||||||
| Mycophenolate | 93 (100.00) | 40 (100.00) | 7 (100.00) | 23 (100.00) | 23 (100.00) | 1.000 |
| Tacrolimus | 92 (98.92) | 40 (100.00) | 7 (100.00) | 23 (100.00) | 22 (95.65) | 0.419 |
| Cyclosporin | 1 (1.08) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 1 (4.35) | 0.419 |
| Corticosteroids | 93 (100.00) | 40 (100.00) | 7 (100.00) | 23 (100.00) | 23 (100.00) | 1.000 |
| Urine viral load (copies/mL) | 8.2 × 107 | 7.1 × 108 | 5.4 × 108 | 4.1 × 107 | 2.9 × 107 | <0.001 |
| (IQR: 2.4 × 107, 1.5 × 109) | (IQR: 3.2 × 107, 5.3 × 109) | (IQR: 2.5 × 108, 1.1 × 1010) | (IQR: 1.8 × 107, 2.1 × 108) | (IQR: 1.1 × 107, 1.1 × 108) | ||
| Plasma viral load (copies/mL) | 0 (0, 1.9 × 103) | 1.4 × 103 (0, 3.5 × 104) | 1.7 × 103 (1.0 × 103, 8.3 × 103) | 0 (0, 0) | 0 (0, 0) | <0.001 |
BKPyVAN, BK polyomavirus-associated nephropathy; BKPyV, BK polyomavirus; IQR, interquartile range.
*
Comparison among Proven BKPyVAN, Probable BKPyVAN, Possible BKPyVAN, and Resolving BKPyVAN.